H
Harald Kojzar
Researcher at Medical University of Graz
Publications - 34
Citations - 1089
Harald Kojzar is an academic researcher from Medical University of Graz. The author has contributed to research in topics: Type 1 diabetes & Insulin. The author has an hindex of 11, co-authored 28 publications receiving 841 citations. Previous affiliations of Harald Kojzar include University of Graz.
Papers
More filters
Journal ArticleDOI
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Hood Thabit,Martin Tauschmann,Janet M Allen,Lalantha Leelarathna,Sara Hartnell,Malgorzata E Wilinska,Carlo L. Acerini,Sibylle Dellweg,Carsten Benesch,Lutz Heinemann,Julia K. Mader,Manuel Holzer,Harald Kojzar,Jane Exall,James Yong,Jennifer Pichierri,Katharine D. Barnard,Craig Kollman,Peiyao Cheng,Peter C. Hindmarsh,Fiona Campbell,Sabine Arnolds,Thomas R. Pieber,Mark L. Evans,David B. Dunger,Roman Hovorka +25 more
TL;DR: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level.
Journal ArticleDOI
Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study
Lalantha Leelarathna,Sibylle Dellweg,Julia K. Mader,Janet M. Allen,Carsten Benesch,Werner Doll,M. Ellmerer,Sara Hartnell,Lutz Heinemann,Harald Kojzar,Lucy Michalewski,Marianna Nodale,Hood Thabit,Malgorzata E. Wilinska,Thomas R. Pieber,Sabine Arnolds,Mark L. Evans,Roman Hovorka +17 more
TL;DR: Compared with SAP, 1 week of closed-loop insulin delivery at home reduces mean glucose and increases time in target without increasing the risk of hypoglycemia in adults with relatively well-controlled type 1 diabetes.
Journal ArticleDOI
Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study
Lia Bally,Lia Bally,Hood Thabit,Harald Kojzar,Julia K. Mader,Jehona Qerimi-Hyseni,Sara Hartnell,Martin Tauschmann,Janet M. Allen,Malgorzata E Wilinska,Thomas R. Pieber,Mark L. Evans,Roman Hovorka +12 more
TL;DR: Use of day-and-night hybrid closed-loop insulin delivery under unsupervised, free-living conditions for 4 weeks in adults with type 1 diabetes and HbA1c below 7·5% is safe and well tolerated, improves glucose control, and reduces hypoglycaemia burden.
Journal ArticleDOI
Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy
Katharine D. Barnard,T. Wysocki,Vanessa Ully,Julia K. Mader,Thomas R. Pieber,Hood Thabit,Martin Tauschmann,Lalantha Leelarathna,Sara Hartnell,Carlo L. Acerini,Malgorzata E. Wilinska,Sibylle Dellweg,Carsten Benesch,Sabine Arnolds,Manuel Holzer,Harald Kojzar,Fiona Campbell,James Yong,Jennifer Pichierri,Peter Hindmarsh,Lutz Heinemann,Mark L. Evans,Roman Hovorka +22 more
TL;DR: This analysis characterizes the impact of the technology, positive and negative aspects of living with the device, alongside participants’ expectations, hopes, and anxieties, and indicates moderately favorable impact of, and satisfaction with, both open and closed loop interventions.
Journal ArticleDOI
Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes.
Gianluca Musolino,Klemen Dovc,Charlotte K. Boughton,Martin Tauschmann,Martin Tauschmann,Janet M. Allen,Katrin Nagl,Maria Fritsch,James Yong,Emily Metcalfe,Dominique Schaeffer,Muriel Fichelle,Ulrike Schierloh,Alena Gerlinde Thiele,Daniela Abt,Harald Kojzar,Julia K. Mader,Sonja Slegtenhorst,Nicole L Ashcroft,Malgorzata E. Wilinska,Judy Sibayan,Nathan Cohen,Craig Kollman,Sabine E. Hofer,Elke Fröhlich-Reiterer,Thomas Kapellen,Carlo L. Acerini,Carine de Beaufort,Fiona Campbell,Birgit Rami-Merhar,Roman Hovorka +30 more
TL;DR: To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day‐and‐night hybrid closed‐loop insulin delivery, a large number of families opted for the day-and-night approach.